Sorrento Therapeutics Inc
Change company Symbol lookup
Select an option...
SRNEQ Sorrento Therapeutics Inc
SPI SPI Energy Co Ltd
AMC AMC Entertainment Holdings Inc
BOF BranchOut Food Inc
KITT Nauticus Robotics Inc
EAT Brinker International Inc
JCSE JE Cleantech Holdings Ltd
GVP GSE Systems Inc
CURV Torrid Holdings Inc
APRN Blue Apron Holdings Inc

Health Care : Biotechnology | Small Cap Value
Company profile

Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next-generation of cancer therapeutics. The Scilex segment is organized around its non-opioid pain management operations and clinical pipeline. The Company’s immuno-oncology platforms, including its fully human antibodies (G-MAB library), ACEA small molecule library, immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs) and oncolytic virus (Seprehvec). The Company is also developing potential antiviral therapies against COVID-19, including FUJOVEE (Abivertinib) and its rapid diagnostic test, including COVIMARK.

Closing Price
Day's Change
-0.0062 (-6.19%)
B/A Size
Day's High
Day's Low
(Below Average)

10-day average volume:

PayPal and Dropbox stocks fall after downgrades, GM shares inch higher, and more stocks on the move

11:41 am ET September 18, 2023 (MarketWatch)

By MarketWatch

Iovance shares continue to rise and Axcella's stock resumes decline

Here are some of the most notable stock movers on Monday.

Stock gainers:

MariaDB PLC shares(MRDB) jumped 9% after venture capital group Runa Capital said Friday it had offered to buy the system software group for 56 cents a share in cash, representing a premium of around 24% based on the Sept. 13 closing price for MariaDB shares.

DoorDash Inc. shares (DASH) were up 1.6% after Mizuho upgraded the stock to buy.

Iovance Biotherapeutics Inc.(IOVA) shares jumped 16%. Shares of the biotechnology company were building on gains seen last Friday after the U.S. Food and Drug Administration agreed to expedite the remaining review of its Biologics License Application for lifileucel, a melanoma-treatment drug.

Stock decliners:

Shares of General Motors Co. (GM) rfell 0.8% as investors continued to watch a standoff between that automaker and two others -- Ford Motor Co. (F) and Stellantis NV (STLAM.MI), where workers at three plants have gone on strike. On Sunday, the president of the United Auto Workers (UAW) rejected Stellantis's wage-hike offer of 21% with an immediate 10% increase at the time of approval. Ford was down 1.7% and Stellantis' U.S.-based shares were down 1.6%.

Axcella Health Inc. shares (AXLA) fell 8%. Shares slumped Friday after the biotech company announced plans for a 1-for-25 reverse stock split. The split, which will be effective Sept. 19, is intended to help the company regain Nasdaq compliance.

Dropbox Inc. shares (DBX) were declining 1.1% after a downgrade at William Blair. Analyst Jason Ader cited "lackluster organic revenue growth prospects in 2024," among other reasons for caution. He cut his rating to market perform from outperform.

Shares of NetApp Inc.(NTAP) were off 2.5% after William Blair's Ader downgraded that stock as well. Various factors "put in doubt the company's ability to achieve sustained high-single-digit revenue growth," he wrote, in moving to a market-perform rating from his prior bullish stance.

PayPal Holdings Inc.'s stock (PYPL) was off a1.5% after SVB MoffettNathanson analyst Lisa Ellis lowered her rating to market perform from outperform. "Looking forward, unfortunately, we expect PayPal's gross-profit growth to remain lackluster," Ellis wrote.

Arm Holdings Plc.'s stock fell 6%, after Bernstein, which didn't help underwrite the company's initial public offering last week, has already weighed in with a bearish rating on the stock.

Canopy Growth Corp.'s stock (WEED.T) fell 14%, after the Canadian cannabis company announced a private placement of up to $50 million as it again moves to boost liquidity. T


This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.


(END) Dow Jones Newswires

September 18, 2023 11:41 ET (15:41 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.